DNA Blood Test Improves Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer

Reston, VA (July 16, 2026)—A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from ²²³Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating this new approach to DNA profiling into clinical practice has the potential to refine patient selection, enable early detection of treatment resistance, and optimize personalized management for prostate cancer patients.

²²³Ra dichloride is a bone-targeted radiopharmaceutical therapy shown to improve overall survival and quality of life in patients with mCRPC. However, clinical outcomes with ²²³Ra vary among patients, and no reliable biomarker has been established to predict or monitor treatment response. As such, there remains an unmet need for robust prognostic and monitoring biomarkers in patients receiving ²²³Ra.

“Circulating tumor DNA (ctDNA) testing—a simple blood test—has emerged as a promising approach to advance precision oncology,” said Masaki Shiota, MD, PhD, associate professor in the Department of Urology in the Graduate School of Medical Sciences at Kyushu University in Fukuoka, Japan. “Compared to tumor biopsies, ctDNA can be collected less invasively and repeatedly, providing a real-time genomic snapshot of the tumor and its heterogeneity that could provide valuable information in the context of ²²³Ra therapy.”

As research on ctDNA profiling in ²²³Ra radiopharmaceutical therapy for mCRPC is scarce, Shiota and colleagues sought to investigate its genomic landscape and clinical utility. The study included 93 mCRPC patients who underwent targeted ctDNA testing using an 88-gene panel before and after receiving ²²³Ra therapy. Associations between ctDNA profiles and clinical outcomes, including biomarker response, radiographic progression-free survival, and overall survival, were analyzed.

Patients with a higher amount of tumor DNA in the blood or certain gene changes, such as TP53, PTEN, and cell cycle pathway alterations, detected through ctDNA testing before treatment were found to have worse outcomes. The analysis also showed that changes in tumor DNA during treatment reflected treatment response and disease trajectory.

“While ²²³Ra is an important treatment for prostate cancer that has spread to the bones, not all patients benefit equally,” said Shiota. “Our findings suggest that a blood-based genomic test may help identify patients who are more likely or less likely to benefit from the therapy. This could help doctors choose treatment more carefully and monitor patients more closely, with the goal of providing more personalized care.”

Graphical Abstract: Changes in circulating tumor DNA during ²²³Ra treatment reflect disease course in patients with bone-metastatic castration-resistant prostate cancer.

The authors of “Circulating Tumor DNA Genomic Profiling in ²²³Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study” include Masaki Shiota and Masatoshi Eto, Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Maki Fujiwara, Takayuki Sumiyoshi, and Takashi Kobayashi, Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Hideki Enokida, Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; Tomomi Kamba, Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tsukasa Igawa, Department of Urology, School of Medicine, Kurume University, Kurume, Japan; Naoya Masumori, Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan; Hirotsugu Uemura, Department of Urology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan; Toshiyuki Kamoto, Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; Katsuyoshi Higashijima, Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Kensuke Mitsunari, Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; Hiroji Uemura, Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan; Shusuke Akamatsu, Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, and Department of Urology, Graduate School of Medicine, Nagoya University, Nagoya, Japan; Shoji Tokunaga, Clinical Therapeutic Trial Center, Ehime University Hospital, Japan; and Takuro Isoda and Kousei Ishigami, Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Visit the JNM website for the latest research and follow us on our Twitter and Facebook pages @JournalofNucMed and follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected].

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.